Pediatric Hypertension Noon Conference 03.20.2019
Pediatric Hypertension Noon Conference 03.20.2019
Pediatric Hypertension Noon Conference 03.20.2019
Pediatric
Hypertension
And how to fix it.
Clark Crane, MD
Noon Conference, 3/20/19
Objectives
An 11 year old boy presents for a routine well child check. While
reviewing the chart, you note that Epic flags his BP of 122/82 as
>95%ile for his age and height. What do you do next?
A. Have the MA recheck the blood pressure
B. Confirm the BP with auscultation
C. Follow-up in 6 months for BP check
D. Start amlodipine
E. Ignore it; he was upset
Prevalence depends on definition
Increase of “elevated blood pressure” when using
new guidelines
~14-16% prevalence of elevated blood pressure, 2-4%
with hypertension
Interestingly, prevalence decreased from 2001 to 2016
looking at NHANES data
It is well established that HTN and elevated BP in childhood increases risk of adult HTN
and metabolic syndrome
Some studies suggest correlation between childhood SBP and adult CAD
Diagnosis of exclusion;
Multifactorial; renal salt
more likely in school-
retention, increased
aged children and
RAAS, endothelial
adolescents who have a
dysfunction,
family history of HTN, and
catecholamines
are overweight or obese
Etiology: Secondary Hypertension
Potentially curable
Pediatrics.
2017 Sep;140(3).
pii: e20171904.
Oscillometric devices are sufficient for screening
but any elevated values should be confirmed by
auscultation
Consider ABPM for confirmation if elevated
BP category for over 1 year or stage I HTN
for more than 3 clinic visits
History of prematurity <32 week’s gestation or small for gestational age, very low birth weight, other neonatal
complications requiring intensive care, umbilical artery line
Congenital heart disease (repaired or unrepaired)
Recurrent urinary tract infections, hematuria, or proteinuria
Known renal disease or urologic malformations
Family history of congenital renal disease
Solid-organ transplant
Malignancy or bone marrow transplant
Treatment with drugs known to raise BP
Other systemic illnesses associated with HTN (neurofibromatosis, tuberous sclerosis, sickle cell disease,114 etc)
Evidence of elevated intracranial pressure
Seated in a quiet room for 3–5 min before measurement, with the back supported and feet uncrossed
on the floor.
BP should be measured in the right arm. The arm should be at heart level, supported, and uncovered
above the cuff. The patient and observer should not speak while the measurement is being taken.
The correct cuff size should be used. The bladder length should be 80%–100% of the circumference of
the arm, and the width should be at least 40%.
Auscultatory BP:
Bell of the stethoscope should be placed over the brachial artery in the antecubital fossa, and
the lower end of the cuff should be 2–3 cm above the antecubital fossa. The cuff should be
inflated to 20–30 mm Hg above the point at which the radial pulse disappears.
Deflate at a rate of 2–3 mm Hg per second. The first (phase I Korotkoff) and last (phase V
Korotkoff) audible sounds should be taken as SBP and DBP.
Pediatrics. 2017 Sep;140(3). pii: e20171904.
Auscultation vs Oscillometric
Oscillometric devices derive SBP and DBP by measuring MAP based upon pressure
oscillations of the brachial artery wall as the cuff is deflated
Appropriate to use for screening (assuming the device is validated in a pediatric age
group)
Measurements > 90th percentile need to be repeated by auscultation
Oscillometric BP generally higher (~2.53mmHg), worse in non-validated devices and younger ages
J Hypertens. 2010;28:e423–e424
≥95th percentile to <95th percentile + 12 mmHg
Discuss lifestyle
At follow-up, your patient’s blood pressure is worse. It is now slightly over the 95%ile
and, after confirming this on 3 separate occasions, you have diagnosed him with
stage I hypertension. Physical exam is only notable for BMI 90%ile for age. Both his
parents are being treated for essential hypertension. How do you proceed?
A. Continue to emphasize lifestyle interventions without additional workup
B. Obtain BMP, UA, CBC, lipids, A1c
C. Obtain the above plus additional labs and imaging to evaluate the most common causes
of secondary hypertension
D. Refer to Nephrology
Evaluation
Goal is to identify possible secondary cause of hypertension and to evaluate for target organ damage
Stage I HTN
Renal Function Panel
UA (protein), urine culture
Urine protein/creatinine ratio
CBC
TSH, fT4
Lipid panel, A1c
Stage II
Renin and aldosterone
If proteinuria, consider C3 and C4, ANA, dsDNA
Evaluation: Imaging
Weight loss has only been shown to reduce blood pressure in adults; like many others,
the pediatric recommendations are extrapolated from adult data.
A. True
B. False
Weight loss!
2014 systematic review showed obesity intervention regimens reduced BP with a mean
decrease of 1.64 mmHg (95% CI -2.56 to -0.71) in systolic BP (SBP) and 1.44 mmHg (95% CI -
2.28 to -0.60) in diastolic BP (DBP).
Similar to results seen in adults (~1 mmHg for every 1 kg lost)
Combined diet and physical activity interventions led to a significantly greater reduction
in both systolic BP and diastolic BP than the diet-only or physical activity-only intervention
Best for use in proteinuric renal disease, diabetes, heart failure, high renin activity
Avoid in bilateral renal artery stenosis, solitary kidney, hyperkalemia, pregnancy
Class example: Lisinopril
Start 0.07-0.1 mg/kg/dose daily
Can increase up to 0.6 mg/kg/day, max 40 mg/day
Typical starting adolescent/adult dose is 5 or 10 mg
Counsel about fluid intake; kidneys (SCr) can be very sensitive to volume depletion
Side effects: dizziness, increased SCr (less than 30% acceptable), hyperkalemia,
cough, teratogenicity (protect the kidneys at the cost of kidneyless babies)
Case
Your patient is tolerating lisinopril well at a 6 week follow-up. The follow-up chemistry was
normal. Blood pressures are improved but still remain elevated above your goal. What do
you do next?
A. Be content with the progress made
B. Increase the dose
C. Add a second agent
D. Refer to Nephrology
Begin with lowest dose of a single agent
Limited evidence to guide best initial agent
Provider comfort level and guided by
comorbidities
All are likely equally effective and safe
If uncomfortable